S&P 500 Industrials Sector SEC Filings — March 09, 2026

09-03-2026

Corbus Pharmaceuticals reported encouraging CRB-701 Phase 1/2 data at ESMO 2025 with unconfirmed ORR of 47.6% in HNSCC, 37.5% in cervical cancer, and favorable safety; CRB-913 Phase 1a showed 2.9% placebo-adjusted weight loss at 14 days with good GI tolerability. The company raised $75M in a Q4 public offering, extending cash runway to $163.3M into 2028. However, Q4 net loss widened to $20.6M ($1.25/share) from $9.5M ($0.78/share) YoY due to operating expenses rising 74% to $22.0M, primarily from R&D, and full-year net loss increased to $78.5M from $40.2M.

• ·CRB-601 Phase 1 completed and deprioritized; no additional patients planned.
• ·FDA Fast Track designations for CRB-701 in HNSCC and cervical cancer.
• ·Upcoming: CRB-701 FDA update Q1 2026, monotherapy data mid-2026, +Keytruda combo Q4 2026; CRB-913 CANYON-1 completion summer 2026.
• ·No grade 4/5 treatment-related AEs for CRB-701; low peripheral neuropathy and skin toxicity.
• ·CRB-913: highest SAD dose 600 mg/day, MAD 150 mg/day; no vomiting, constipation, nausea; negative neuropsychiatric assessments.

09-03-2026

Voyager Technologies reported record Q4 2025 net sales of $46.7M, up 24% YoY (46% adjusted), and full-year sales of $166.4M, up 15% YoY (27% adjusted), driven by 63% YoY growth in Defense and National Security to $35.7M in Q4, while Space Solutions declined 29% YoY to $12.5M due to NASA contract wind-down; full-year backlog hit a record $265.6M (+33% YoY) with liquidity at $704.7M (+15% sequential). However, the company posted Q4 net loss of $30.2M and full-year net loss of $116.1M, alongside raised 2026 revenue guidance of $225-255M (35-53% YoY growth). Five strategic acquisitions, including ExoTerra Resource and Estes Energetics, bolstered capabilities.

• ·Q4 non-GAAP adjusted loss of $21.7M and adjusted loss per share of $(0.37); full year non-GAAP adjusted loss of $82.4M and adjusted loss per share of $(2.05).
• ·Q4 Non-GAAP Adjusted EBITDA of $(21.8)M; full year $(69.9)M.
• ·Q4 innovation spend 132% of net sales on consolidated basis.
• ·Starlab achieved 10 NASA milestones in 2025 (4 in Q4), 31 total to date.
• ·Earnings conference call scheduled for March 10, 2026, at 9 a.m. ET.

09-03-2026

Casey's reported strong Q3 FY2026 results with net income of $130.1M, up 49.3% YoY, diluted EPS of $3.49, up 49.8%, and EBITDA of $308.9M, up 27.5%, driven by inside same-store sales growth of 4.0% and margin expansion to 42.2%, plus fuel gross profit up 15.3% to $348.2M despite modest same-store fuel gallons growth of 0.4%. However, operating expenses rose 4.1% YoY to $697.6M, partly due to higher labor rates, snow removal, and incentive compensation, while same-store operating expenses excluding credit card fees increased 4.6%. Total revenue reached $3.92B, up slightly, with Casey’s Rewards surpassing 10M members.

• ·Q3 inside sales up 5.7% YoY to $1.48B; prepared food/dispensed beverage SSS +4.3%, grocery/general merchandise SSS +4.0%.
• ·Fuel total gallons sold +2.3% YoY to 848.4M gallons; sold $6.3M in RINs.
• ·Board approved quarterly dividend of $0.57/share, payable May 15, 2026 to shareholders of record May 1, 2026.
• ·FY2026 outlook: EBITDA +18-20%; inside SSS +3.5-4.5%, margin 41.5-42.5%; op ex +10%; fuel SSS gallons -1% to +1%; at least 80 new stores.
• ·Remaining share repurchase authorization: $157M.

09-03-2026

Product revenue grew significantly to $72.2M from $7.3M YoY while supply agreement revenue increased substantially, but total revenue declined 5% YoY to $84.3M due to an 88% drop in collaboration revenue to $9.7M. Operating expenses surged 186% to $263.7M, driven by a 221% rise in SG&A to $230.1M, leading to a net loss of $171.3M versus $8.0M profit in 2024. Stockholders' equity fell to $114.3M from $256.8M amid heavy operating cash use of $170.9M.

• ·Net cash used in operating activities: $170.9M in 2025 vs provided $13.5M in 2024.
• ·Cash and equivalents decreased by $9.5M net in 2025.
• ·Total assets: $327.7M at Dec 31 2025 (down from $351.2M).
• ·Accumulated deficit: $294.6M at Dec 31 2025 (up from $123.3M).
• ·Term loans, net: $96.4M at Dec 31 2025 (none in 2024).
• ·Auditor focus: rebates estimation as key audit matter.

09-03-2026

Brand Engagement Network, Inc. completed the third and final closing of a previously announced $1.518M private placement with Ben Capital Fund I, LLC on March 9, 2026, receiving the final $506K installment. The transaction involved the sale of 24,000 shares of common stock at $63.25 per share, funded in three equal installments. No other material changes or performance metrics were reported.

• ·Shares sold at $63.25 per share
• ·Securities offered under Section 4(a)(2) exemption of the Securities Act of 1933
• ·Previously disclosed in 8-K filed January 30, 2026

09-03-2026

PharmaCyte Biotech, Inc. (PMCB) filed a DEF 14A proxy statement on March 9, 2026, for its virtual annual stockholder meeting on March 30, 2026, at 11:00 a.m. ET, with record date January 30, 2026. As of the record date, 10,735,649 common shares were outstanding, plus 2,677,093 as-converted votes from Series C Preferred Stock. The filing includes pay versus performance disclosures for executives Joshua N. Silverman and Kenneth L. Waggoner covering fiscal years ended April 30, 2023, 2024, and 2025, though specific compensation values are not detailed in the provided content.

• ·Annual meeting held virtually; access via http://www.web.viewproxy.com/PMCB/2026
• ·Fiscal year end: April 30
• ·Transfer agent: Equiniti Trust Company, LLC
• ·Business address: 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169

09-03-2026

Innovation Beverage Group Limited filed a preliminary F-1 registration statement on March 9, 2026, for a proposed public offering of up to $15,000,000 through up to 4,166,667 Ordinary Units (each consisting of one Ordinary Share, one Series A Warrant, and one Series B Warrant) or Pre-Funded Units, with Aegis Capital Corp. as placement agent. The prospectus incorporates prior filings including Form 8-A from September 16, 2024, and details historical unregistered securities issuances from 2023-2024 totaling various small share grants and private placements exempt under Sections 4(a)(2), Reg D, Reg S, and Rule 701. No financial performance metrics or period-over-period comparisons are provided in this filing.

• ·Historical unregistered issuances include a 5:1 share consolidation in 2025 affecting share counts.
• ·F-1 amendments filed multiple times from February 28, 2025, through February 24, 2026.
• ·Company address: 29 Anvil Road, Seven Hills, NSW 2147, Australia.

09-03-2026

On March 6, 2026, Phillips 66's Board of Directors increased its size from 14 to 16 members and appointed Kevin O. Meyers (age 72) and Howard I. Ungerleider (age 57) as independent directors, effective immediately. Meyers was assigned to the class expiring in 2027 and Ungerleider to the class expiring in 2026; both joined the Audit & Finance Committee and Public Policy and Sustainability Committee. In connection, Grace Puma Whiteford was reclassified as a Class I director with term expiring in 2028.

• ·No arrangements or understandings for appointments; no material interests under Item 404(a) of Regulation S-K.
• ·Pro-rated compensation per standard non-employee director arrangements described in April 8, 2025 proxy statement.

09-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed a Form 8-K on March 9, 2026, under Items 8.01 and 9.01, announcing the issuance of a press release titled 'The Top 20 Things You Probably Did Not Know About AITX and RAD', attached as Exhibit 99.1. The information is furnished and explicitly stated as not material or filed for liability purposes under the Exchange Act.

09-03-2026

Pantages Capital Acquisition Corp, a blank check company, reported total assets of $90.4M as of Dec 31, 2025, up from $87.2M prior year, driven by growth in the Trust Account to $90.1M (+4.1%) from interest income of $3.6M. However, cash declined sharply to $0.19M from $0.53M (-65%), operating losses widened to $1.02M from $0.35M, and shareholders' deficit deepened to $(1.38M) from $(0.36M). Net income turned positive at $2.55M (vs prior loss of $0.09M), primarily from Trust interest, with EPS of $0.23.

• ·Prepaid expenses declined to $87,377 from $122,434.
• ·Accounts payable and accrued expenses decreased to $78,128 from $121,039.
• ·Due to related parties minimal at $294 (down from $33,521).
• ·Basic and diluted EPS for redeemable Class A shares: $0.23 in 2025 vs $(0.03) in 2024.

09-03-2026

Cumberland Pharmaceuticals Inc. reported net revenues of $44.5M for the year ended December 31, 2025, up 17.6% YoY from $37.9M, driven by strong growth in Sancuso (+32% to $11.9M), Vibativ (+33% to $9.5M), new Talicia ($3.3M), and Other (+211% to $4.1M). However, Kristalose revenues declined 31% to $10.5M and Caldoror fell 6% to $4.7M; operating loss narrowed to $2.8M from $6.4M but remained negative, with net loss at $2.9M versus $6.4M prior year. Cash and equivalents decreased to $11.4M from $18.0M, working capital dropped sharply to $0.3M from $4.8M, and current ratio slipped to 1.0x from 1.2x.

• ·Cash from operating activities improved to $4.9M in 2025 from -$0.6M in 2024.
• ·Vibativ contribution margin: $7.6M in 2025 vs. $3.6M in 2024.
• ·Sancuso contribution margin: $7.2M in 2025 vs. $4.4M in 2024.
• ·Revolving line of credit availability increased to $9.8M from $4.7M.

09-03-2026

Sphere 3D Corp. reported FY2025 revenue of $11.2 million, down 32.5% YoY from $16.6 million in 2024, primarily due to the April 2024 Bitcoin halving and equipment replacement. Operating costs and expenses decreased 12.6% to $33.2 million, with G&A expenses falling 33% to $8.3 million; however, net loss widened to $21.5 million from $9.5 million amid lower investment gains and higher impairments. The company mined 111.6 Bitcoin, held 37.3 Bitcoin at year-end, improved fleet efficiency to below 19.0 J/TH from 27.1 J/TH, and announced a merger with Cathedra Bitcoin.

• ·Impairment of property and equipment increased to $7.2M in FY2025 from $1.1M in FY2024.
• ·Cash and cash equivalents decreased to $3.7M as of Dec 31, 2025 from $5.4M as of Dec 31, 2024.
• ·Investment in equity securities dropped to $0 from $7.5M as of Dec 31, 2024.

09-03-2026

Great Lakes Dredge & Dock Corp (GLDD) reported strong FY2025 results with contract revenues increasing 16.5% YoY to $888M from $763M in 2024, gross profit up 26.7% to $203M, operating income up 37.7% to $128M, and net income surging 28.4% to $73M (diluted EPS $1.08 vs $0.84). Total assets grew modestly 2.4% to $1.286B, equity rose 15.3% to $517M, and operating cash flow jumped 252% to $247M; however, accounts receivable declined sharply 40.5% to $70M, current assets fell 17.5% to $217M, and total liabilities decreased due to debt reduction but deferred taxes rose 31.7%. Capex increased to $147M amid property and equipment net up 14.2% to $803M, with $12M in common stock repurchases.

• ·Long-term debt decreased 15.6% to $378M from $448M.
• ·Deferred income taxes increased 31.7% to $104M from $79M.
• ·Cash paid for interest $30M in 2025 vs $30M in 2024 (flat).
• ·Loss on extinguishment of debt $11M in 2025.
• ·Repaid $100M Second Lien Term loan in 2025.

09-03-2026

Longeveron Inc. reported the immediate resignation of Board member and Audit Committee chairman Richard Kender on March 3, 2026, due to his new role as Executive Chairman and Interim CEO at Seres Therapeutics, resulting in temporary non-compliance with Nasdaq Listing Rule 5605(c)(2)(A) for lacking three independent audit committee members and a financial expert. On March 4, 2026, the company appointed existing Board member Dr. Roger Hajjar to the Audit Committee, restoring the minimum three independent members but still without a financial expert. Longeveron plans to appoint or elect a qualified independent audit committee financial expert within the 180-day cure period or at the next annual shareholders' meeting.

• ·Resignation not due to any disagreement with company operations, policies, practices, management, or Board.
• ·Seres Therapeutics announced Kender's new role on March 2, 2026.

09-03-2026

908 Devices Inc. reported total revenue of $56.2M for the year ended December 31, 2025, up 17.7% YoY from $47.7M in 2024, driven by strong growth in recurring revenue (+22.0% to $19.4M), U.S. state/local sales (+38.2% to $24.2M), rest of world (+21.4% to $14.4M), and global pharmaceutical/industrial (+98.7% to $3.0M). However, U.S. federal and defense revenue declined 13.6% to $14.5M, contract revenue fell 11.4% to $0.1M, and device sales growth slowed to 15.7% at $36.7M, amid risks from long sales cycles and heavy reliance on government contracts.

• ·Over 700 customers including major government institutions.
• ·Risks include long and unpredictable sales cycles, heavy dependence on U.S. government orders, and potential impacts from government contracting/fiscal policy changes.

09-03-2026

Battalion Oil Corporation entered into a definitive agreement to raise approximately $15 million gross ($14.1 million net after fees) through a private placement of common stock at $5.50 per share and/or prefunded warrants with a new institutional investor, with Roth Capital Partners as sole placement agent. The offering is expected to close on March 4, 2026, subject to customary conditions, with proceeds intended for working capital and general corporate purposes. The company also noted an increase in average oil production of approximately 1,200 net barrels per day in January compared to December.

• ·Expected closing date: March 4, 2026, subject to customary conditions
• ·Company to file resale registration statement on Form S-3 within 20 days of closing
• ·Securities offered in unregistered private placement under Securities Act exemptions
• ·Oil production increase of approximately 1,200 net barrels per day (January vs. December)

09-03-2026

Alexander’s, Inc. (NYSE: ALX) entered into an agreement to sell its unencumbered Rego Park I property in Queens, New York, to Northwell Health, Inc., for a gross purchase price of $235.5M and net proceeds of $202M, expecting a financial statement gain of approximately $147M. The 338,000 sq ft vacant structure on 5.9 acres, built in 1959 with a 1,236-space parking garage, was recently vacated by relocating tenants to adjacent Rego Park II. The sale is subject to customary closing conditions and expected to close by Q3 2026.

• ·Rego Park I located at intersection of Queens Boulevard and Junction Boulevard, adjacent to Long Island Expressway
• ·Property built in 1959 as three-story vacant structure
• ·Tenants relocated to adjacent Rego Park II shopping center
• ·Contact phone: (201) 587-8541

09-03-2026

enGene Holdings Inc. reported a widened net loss of $29.8M for the three months ended January 31, 2026, up 21% YoY from $24.6M, driven by increased R&D expenses ($22.3M, +11%) and G&A expenses ($8.9M, +35%), with operating cash use rising to $28.9M from $25.7M. However, the company raised $126.3M gross from a public offering and $23.2M from pre-funded warrants, plus $25M from a Second Amended Term Loan, boosting total assets to $337.1M (up 52% QoQ from $221.5M) and shareholders' equity to $281.5M (up 68% QoQ). Cash and equivalents declined to $36.6M amid heavy investments in marketable securities.

• ·Loss per share improved to $0.44 from $0.48 YoY due to increased share count.
• ·Weighted-average shares outstanding: 67.3M in 2026 vs 51.0M in 2025.
• ·Marketable securities short-term increased to $239.3M from $143.6M QoQ.

09-03-2026

Dianthus Therapeutics announced an early GO decision in the Phase 3 CAPTIVATE CIDP trial, achieving 20 confirmed responders with fewer than 40 participants completing open-label Part A, ahead of Q2'26 guidance. FY2025 financials showed a strong cash position of $514.4 million (runway into 2028) and total assets of $530.9 million (up from $374.0 million in FY2024), but R&D expenses rose 75% YoY to $145.6 million, G&A expenses increased 37% to $34.3 million, and net loss widened 91% YoY to $162.3 million ($4.20 per share) from $85.0 million ($2.55 per share). Upcoming catalysts include Phase 3 gMG trial initiation mid-2026 (topline 2H'28), MoMeNtum MMN topline 2H'26, and DNTH212 Phase 1 data 2H'26.

• ·Stock-based compensation in R&D: $10.1M FY2025 (vs $5.6M FY2024)
• ·Stock-based compensation in G&A: $12.7M FY2025 (vs $7.3M FY2024)
• ·CAPTIVATE GO criteria: ≥50% response rate (≥20/40 responders)
• ·Conference call: March 9, 2026 at 8:00 a.m. ET

09-03-2026

Ionis Pharmaceuticals announced that long-serving directors B. Lynne Parshall (since September 2000) and Joseph Wender (since January 1994, lead independent director since 2020) will retire at the end of their terms on June 4, 2026. Peter N. Reikes will rejoin the Board effective the same date, bringing expertise from recent roles at ARPA-H and FDA, as well as prior investment banking positions at Stifel, Cowen, and PaineWebber. The changes reflect planned transitions amid the company's growth, with no immediate disruptions noted.

• ·Parshall served as COO (Dec 2007-Dec 2017) and CFO (Jun 1994-Dec 2012)
• ·Wender joined Goldman Sachs in 1971, general partner in 1982, senior consultant since Jan 2008
• ·Reikes: Senior strategy advisor at ARPA-H (Dec 2024-Feb 2026), FDA senior advisor (prior 3+ years), previously Ionis director (2018-2021)
• ·Reikes education: B.A. Economics (UCLA), M.B.A. Finance (Wharton)

09-03-2026

On March 3, 2026, Lightpath Fiber Issuer LLC, a bankruptcy-remote indirect subsidiary of Optimum Communications, Inc., completed a $1.657B securitization financing by issuing Secured Fiber Network Revenue Notes, Series 2026-1, consisting of $1.527B Class A-2 Notes at 5.597% interest and $130M Class B Notes at 5.890% interest. The net proceeds were used to repay in full $1,553.3M of existing debt, including 5.625% senior notes due 2028, 3.875% senior secured notes due 2027, and a term loan facility, with remaining proceeds for general corporate purposes. The notes are secured by fiber network assets and customer contracts in New York City, Boston metro areas, New Jersey, Connecticut, Pennsylvania, and Virginia, with an anticipated repayment date of March 25, 2031, and legal final maturity in March 2056.

• ·Notes subject to rapid amortization if debt service coverage ratio fails to meet thresholds.
• ·Securitized assets include fiber network assets and customer contracts in New York City, Boston metro areas, New Jersey, Connecticut, Pennsylvania, and Virginia.
• ·Legal final maturity date of the Notes: March 2056.

09-03-2026

Xenon Pharmaceuticals Inc. announced topline data from its Phase 3 X-TOLE2 study of azetukalner in focal onset seizures via a press release (Exhibit 99.1) and investor presentation (Exhibit 99.2), furnished under Regulation FD Disclosure on March 9, 2026. The disclosures are not deemed filed and include forward-looking statements with associated risks. No specific topline results or metrics are detailed in the filing itself.

• ·Filing date and earliest event reported: March 9, 2026
• ·Registrant address: 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8
• ·Telephone: (604) 484-3300
• ·Securities: Common Shares, without par value (XENE) on Nasdaq Global Market

09-03-2026

Amex GBT reported strong Q4 FY2025 revenue of $792M (+34% YoY) and full-year revenue of $2.718B (+12% YoY), driven by the CWT acquisition, with Adjusted EBITDA of $130M (+17%) and $532M (+11%) respectively; however, gross margins declined 243bps to 55% in Q4 and 15bps to 57% FY, Adjusted EBITDA margins fell 233bps to 16% in Q4 while flat at 20% FY, and free cash flow dropped sharply to $13M (-66%) in Q4 and $104M (-37%) FY. The company reiterated FY2026 guidance for 19-21% revenue growth to $3.235B-$3.295B and Adjusted EBITDA of $615M-$645M (+16-21%), doubled share buyback authorization to $600M, and highlighted 96% customer retention and $3.3B in Total New Wins Value.

• ·Q4 TTV growth of 45% and Transaction Growth of 37%, FY TTV 17% and Transaction Growth 14%, primarily due to CWT acquisition, business travel demand, and share gains.
• ·Excluding CWT, Q4 revenue growth was 8%.
• ·Net Debt / LTM Adjusted EBITDA improved slightly to 1.9x from 1.8x.
• ·CWT acquisition closed in September 2025.
• ·Next-gen Egencia launching in April 2026 with AI features.

09-03-2026

Heritage Insurance Holdings reported record Q4 2025 net income of $66.7 million, up 228.5% YoY from $20.2 million, driven by a net combined ratio of 62.0% (improved 27.7 points from 89.7%) and net loss ratio of 31.3% (down 23.4 points); full-year 2025 net income was $195.6 million, up 217.8% YoY from $61.5 million. However, gross premiums written declined 0.7% to $336.2 million, policies in force dropped 8.3% to 357,275, premiums in force were flat at $1.43 billion (down 0.1%), and gross premiums earned grew only 0.4% to $361.7 million. Book value per share increased 72.5% to $16.39 from year-end 2024.

• ·New business premium production increased 60.4% in Q4 2025 vs Q4 2024.
• ·Net weather losses $7.7M in Q4 2025 accident quarter (down from $45.6M prior year).
• ·Unpaid losses and LAE declined to $579.5M from $1.04B at Dec 31 2024.
• ·Reinsurance recoverable on claims declined to $318.6M from $740.2M at Dec 31 2024.
• ·Florida policies in force down 7.7% to 123,437; Other States down 8.5% to 233,838.
• ·Share repurchase authorization increased to $25M through Dec 31 2026.
• ·Dividend suspension continued to prioritize growth.

09-03-2026

InMed Pharmaceuticals Inc. filed an 8-K on March 9, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, announcing a pharmaceutical development outlook for 2026 via news release (Exhibit 99.1). The disclosure is furnished, not filed, and not subject to liabilities under Section 18 of the Exchange Act or incorporated by reference into other filings.

• ·Registrant is an emerging growth company.
• ·Securities: Common Shares, no par value (INM) on Nasdaq.
• ·Principal executive offices: Suite 1445 – 885 West Georgia Street, Vancouver, British Columbia, Canada V6C 3E8.

09-03-2026

Protagenic Therapeutics, Inc. reported total assets of $4.4M as of Dec 31, 2025, up significantly from $89K at Mar 31, 2025, driven by the acquisition of Phytanix Bio which added $943K cash and $2.1M intangibles; cash increased to $2.2M. However, operating expenses rose 130% YoY to $925K in Q3 FY26, resulting in a $925K operating loss, while 9M net loss widened 112% YoY to $3.7M despite a Q3 net income of $2.2M from $3.1M derivative gain. Cash used in operations was $3.1M over 9M, offset by $4.4M financing inflows.

• ·Notes payable increased to $3.16M from $1.67M.
• ·Accounts payable rose to $2.03M from $961K.
• ·Derivative liabilities decreased to $544K from $1.38M.
• ·Weighted average shares basic/diluted Q3: 1,934,878 vs 5,395,604 YoY.
• ·Reverse merger accounted under ASC 805 with purchase price allocation of $2.34M.

09-03-2026

Alpha Tau Medical Ltd. (DRTSW) filed its 20-F Annual Report on March 09, 2026, disclosing significant losses since inception with no revenue generated to date and expectations of continued losses over the next several years. The company highlights substantial risks including the need for additional funding to avoid delaying or terminating Alpha DaRT® technology development, challenges from its novel radiation therapy approach, lack of commercial marketing experience, limited market opportunities, and potential non-acceptance of foreign clinical trial data by the FDA.

09-03-2026

Voyager Therapeutics reported Q4 2025 collaboration revenue of $15.3 million, up 144% YoY from $6.3 million, driven by Neurocrine agreement recognition, but full-year 2025 revenue declined 50% YoY to $40.4 million from $80.0 million due to lower prior-year milestones. Net loss narrowed to $27.4 million in Q4 from $34.5 million YoY, while full-year net loss widened significantly to $119.7 million from $65.0 million; R&D and G&A expenses remained relatively flat to slightly higher YoY. The company ended 2025 with $202 million in cash, supporting runway into 2028, with key pipeline milestones including VY1706 first-in-human dosing and VY7523 data expected in H2 2026.

• ·Neurocrine triggered $3 million milestone payment to Voyager in Q4 2025 for preclinical toxicology study initiation.
• ·Weighted-average common shares outstanding basic: 58.7 million (FY 2025) vs 57.7 million (FY 2024).

09-03-2026

Gokul Rajaram informed The Trade Desk, Inc. of his resignation from the board of directors on March 3, 2026, effective April 3, 2026; the resignation was not due to any disagreement with the company's operations, policies, or practices. Mr. Rajaram had served on the board since May 2018. The board thanked him for his years of service.

• ·Filing dated March 9, 2026

09-03-2026

Occidental Petroleum (OXY) announced early tender results for its cash tender offers and consent solicitations on several senior notes and debentures, increasing the Aggregate Cap from $700M to $1.2B and fully accepting $21.5M of 0% 2036 Notes and $843.3M of 6.125% 2031 Notes, while prorating acceptance of $335.2M (28.7%) of 6.625% 2030 Notes due to oversubscription. No tenders were accepted for the 7.200% 2029 or 7.950% 2029 Debentures. Requisite consents were obtained only for the 6.125% 2031 Notes amendments, with early settlement on March 9, 2026.

• ·Early Tender Time: 5:00 p.m. NYT on March 4, 2026
• ·Early Settlement Date: March 9, 2026
• ·Tender Offers Expiration Date: March 19, 2026 (unless extended)
• ·Offer to Purchase dated February 19, 2026
• ·Early Tender Premium: $30 per $1,000 principal for accepted notes
• ·Requisite consents not obtained for 6.625% 2030 Notes, 7.200% 2029 Debentures, or 7.950% 2029 Debentures
• ·Accreted value for 0.000% 2036 Notes as of April 10, 2026: approximately $580,925.31 per $1M principal at maturity

09-03-2026

Stock Yards Bancorp, Inc. (SYBT) filed an S-4 registration statement on March 9, 2026, related to its proposed merger with Field & Main Bancorp, under a fixed exchange ratio of 0.6550 SYBT shares per Field & Main share, implying a $44.55 value per Field & Main share based on SYBT's $68.01 closing price on January 26, 2026 (last trading day before merger announcement). Field & Main has 2,372,067 shares outstanding as of March 1, 2026, held by approximately 225 shareholders. The filing highlights ongoing dividends (SYBT at $0.32/share quarterly, Field & Main at $0.25/share) with coordination to avoid overlaps, but cautions on market price fluctuations, integration risks, and no assurance of merger completion.

• ·SYBT common stock trades on NASDAQ under symbol 'SYBT'; Field & Main common stock has no public market.
• ·Field & Main declares dividends in April, July, October, and December (paid January).
• ·Merger agreement prohibits Field & Main from paying dividends beyond customary quarterly amounts.

09-03-2026

On March 5, 2026, Alpha and Omega Semiconductor Limited's Compensation Committee approved an incentive cash bonus plan for the 2026 calendar year, tying executive officer awards to attainment of adjusted earnings per share and revenue goals, with minimum thresholds required for any payout. Bonuses range from $0 to maximums as a percentage of base salary: 220% target for CEO Stephen Chang (target 100%) and 154% for other named executives (target 70%). The full plan details will be filed as an exhibit to the Q1 FY2026 10-Q ending March 31, 2026.

• ·Plan qualified in entirety by full details to be filed in 10-Q for quarter ending March 31, 2026
• ·Aggregate award determined by range of adjusted EPS and revenue attainment levels

09-03-2026

Cypherpunk Technologies Inc. received a Nasdaq notification letter on March 4, 2026, stating that its common stock (CYPH) closing bid price was below the $1.00 per share minimum for 30 consecutive business days, violating Listing Rule 5550(a)(2). The company has 180 days until August 31, 2026, to regain compliance by sustaining a $1.00 closing bid price for 10 consecutive business days, with potential for an additional 180-day period if other listing criteria are met. The company plans to monitor the issue and explore options like a reverse stock split but provides no assurance of success, and trading remains unaffected currently.

• ·Notice does not currently impact listing or trading of CYPH on Nasdaq Capital Market.
• ·Potential additional 180 calendar days compliance if meets market value of publicly held shares and other initial listing standards (except bid price), with written notice to Nasdaq of intent to cure, possibly via reverse stock split.

09-03-2026

Independent Bank Corp. (INDB) filed an 8-K on March 9, 2026, under Regulation FD Disclosure, attaching an investor presentation (Exhibit 99.1) to be used at the 2026 RBC Capital Markets Global Financial Institutions Conference on March 10, 2026. The filing includes no financial results or performance metrics. Signed by Chief Financial Officer Mark J. Ruggiero.

• ·Filing Items: 7.01 (Regulation FD Disclosure), 9.01 (Financial Statements and Exhibits)
• ·Commission File Number: 0000776901
• ·I.R.S. Employer Identification No.: 04-2870273

09-03-2026

Liberty Broadband Corporation announced on March 6, 2026, that it will hold its virtual Annual Meeting of Stockholders on May 11, 2026, at 11:15 a.m. Mountain Time. The disclosure was furnished under Regulation FD via Form 8-K with an attached press release (Exhibit 99.1). No financial or operational metrics were reported.

• ·Securities registered: Series A common stock (LBRDA), Series C common stock (LBRDK), Series A Cumulative Redeemable preferred stock (LBRDP), all on Nasdaq Stock Market LLC.
• ·Principal executive offices: 12300 Liberty Blvd., Englewood, Colorado 80112.
• ·Date of earliest event reported: March 6, 2026; Filing date: March 9, 2026.

09-03-2026

Kronos Worldwide, Inc. reported a Q4 2025 net loss of $82.8 million ($0.72 per share), widening from a $13.2 million loss ($0.12 per share) in Q4 2024, driven by higher unabsorbed fixed production costs from curtailments and lower TiO2 prices, despite higher sales volumes. Full-year 2025 net loss was $110.9 million ($0.96 per share) versus 2024 net income of $86.2 million ($0.75 per share), with net sales down 1% YoY to $1.9B due to 4% lower average TiO2 prices partially offset by higher volumes, while production volumes declined 10% YoY amid 77% capacity utilization versus 96% in 2024. TiO2 segment swung to a Q4 loss of $59.4 million from $33.1 million profit and FY loss of $22.2 million from $141.0 million profit.

• ·Effective July 16, 2024, acquired 50% JV interest in LPC, making it wholly-owned; FY 2024 net income included $64.5M non-cash gain on remeasurement.
• ·Q4 2025 cost of sales included $54M unabsorbed fixed costs; FY 2025 EBITDA included $4.6M non-cash gain on LPC earn-out reduction.
• ·Currency fluctuations (primarily euro) increased net sales by $13M in Q4 2025 and $24M in FY 2025 YoY.
• ·Production capacity: Q1-Q4 2025 at 93%, 81%, 80%, 55%; Q1-Q4 2024 at 87%, 99%, 92%, 97%.

09-03-2026

Trailblazer Merger Corp I received Nasdaq notices on March 3, 2026, indicating failure to meet the $15M MVPHS requirement for 30 consecutive business days and the 1.1M PHS minimum under Nasdaq Global Market rules, with no immediate trading impact but delisting risk if unresolved. The company has 180 days until August 31, 2026, for MVPHS compliance and 45 days to submit a PHS plan (potentially extendable to 180 days). While expecting resolution via its pending business combination with Cyabra Strategy Ltd., no assurance of regaining or maintaining listing.

• ·MVPHS non-compliance based on 30 consecutive business days below threshold
• ·PHS non-compliance requires plan submission within 45 calendar days from March 3, 2026
• ·Potential transfer to Nasdaq Capital Market if Global Market requirements not met

09-03-2026

Genius Group Ltd's 20-F annual report for the year ended December 31, 2025, shows significant improvement in cash flows, with net cash used in operating activities reduced to $10.6M from $46.3M in 2024 (77% less usage) and investing activities using $2.2M versus $8.1M (73% less usage). However, net cash from financing activities declined sharply to $13.9M from $55.4M (75% decrease). Outstanding loans as of December 31, 2025, totaled reductions across most facilities, though new Ledn Lending stood at $8.5M.

• ·Several loans reduced significantly YoY: Lloyds CBIL from $74,344 to $26,626; Funding Circle Loan from $121,576 to $10,520; Arch Lending paid off from $10M to $0.
• ·Upcoming IFRS amendments effective Jan 1, 2026 (IFRS 7/9) and Jan 1, 2027 (IFRS 18/19).
• ·Company qualifies as Emerging Growth Company and Foreign Private Issuer, retaining exemptions from certain U.S. disclosure requirements.

09-03-2026

U.S. Physical Therapy, Inc. (USPH) updated its investor presentation on March 6, 2026, for the year ended December 31, 2025, highlighting 780 owned/managed outpatient physical and occupational therapy clinics across 44 states, $781M TTM revenues with 16% YoY growth, and $95M TTM Adjusted EBITDA. The company generates 85% of revenue from physical therapy operations and 15% from injury prevention services, operating in a highly fragmented >$40B U.S. rehabilitation market where no company holds more than 10% share, and maintains a $1.80 annual dividend.

• ·Headquartered in Houston, TX; founded in 1990.
• ·10-K for year ended December 31, 2025 filed with SEC on February 27, 2026.
• ·Investor presentation available on www.usph.com under Investor Relations.

09-03-2026

Enzon Pharmaceuticals, Inc. issued a press release on March 9, 2026, extending the expiration date of its exchange offer for Series C Non-Convertible Redeemable Preferred Stock to be exchanged for common stock until one minute after 11:59 p.m. Eastern time on March 11, 2026, unless further extended. This update relates to the proposed merger with Viskase Companies, Inc., with references to a Registration Statement on Form S-4 containing details on the transaction.

• ·Exchange offer extended unless further extended
• ·Form S-4 Registration Statement filed with SEC, available at www.sec.gov and https://www.enzon.com
• ·Information under Item 7.01 not deemed 'filed' per General Instruction B.2 of Form 8-K

09-03-2026

MacroGenics reported 2025 full-year revenue of $149.5M, flat YoY compared to $150.0M in 2024, driven by higher contract manufacturing ($52.6M vs $13.1M) offset by lower collaborative revenue. R&D expenses decreased 17% to $147.2M from $177.2M due to program terminations, but net loss widened to $74.6M from $67.0M (which included a $36.3M gain on MARGENZA sale), with cash position at $189.9M (down from $201.7M) supporting runway into late 2027. The company anticipates key 2026 milestones including initial data from MGC026 and MGC028 Phase 1 trials and LINNET study update for lorigerlimab, despite a partial FDA clinical hold on LINNET.

• ·Contract manufacturing revenue increased to $52.6M in 2025 from $13.1M in 2024.
• ·FDA partial clinical hold on LINNET study; no new enrollments.
• ·SG&A expenses decreased to $39.2M in 2025 from $71.0M in 2024.
• ·Total stockholders' equity $55.6M as of Dec 31, 2025 (down from $116.1M in 2024).

09-03-2026

Transcat, Inc. (Nasdaq: TRNS) appointed Jaime Irick as President and Chief Executive Officer effective March 29, 2026, succeeding Lee D. Rudow, who is retiring after 14 years but will serve as a senior advisor through March 2027. Irick, a proven leader with experience at Pittsburgh Paints Company (including a $2B carve-out) and PPG Industries (overseeing $3B in revenue and 7,000+ employees), was also added to the Board and Executive Committee. Chairman Gary Haseley highlighted Irick's track record in growth, integrations like the $1.1B Ennis-Flint deal, and shareholder value creation.

• ·Jaime Irick holds a degree in Systems Engineering from the United States Military Academy at West Point and an MBA from Harvard Business School; prior U.S. Army Field Artillery Officer and Airborne Ranger.
• ·Irick plans to meet investors and analysts after Transcat’s Fourth Quarter and Full Year 2026 conference call and webcast.
• ·Transcat provides services to regulated industries including Life Science (pharmaceutical, biotechnology, medical device), aerospace/defense, energy/utilities; operates calibration labs in U.S., Puerto Rico, Canada, Ireland.